Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Three Equities Under the Influence of Drugs


Biotech sector flourishes as disease rates skyrocket.

As consumer spending takes a hit and service-related companies continue to struggle, some sectors seem to continue to flourish -- namely, biotechnology. And for good reason.

One major reason the sector is flourishing is an aging population that seems to be prone to diseases that cause degenerate-disease rates and cancer rates to increase, driving up the demand for drugs. A second reason is that biotech companies are aiming to increase the scope of their drugs to treat more than just one disease, and to some extent, to make them safe from generic competition. Lastly, innovation is starting to glimmer in the sector as companies compete to produce the next blockbuster drug and favorable clinical trials are completed.

To take it a step further, leaders of the industry are coming together to utilize one another's strengths. This can be seen by the merger between Roche and Genentech (DNA) and the recent takeover of Medarex (MEDX).

Some equities that should feel the impact of the increase in demand for drugs are the following:

1. PowerShares Dynamic Biotech & Genome (PBE) up 47% from a March low of $11.03 to close at $16.25 on August 5.

2. iShares NASDAQ Biotechnology
(IBB) rebounding nicely from a March low of $59.05 to a $78.16 close on August 5, an increase of 32%.

3. Amgen (AMGN) closing at $62.31 on August 5 after hitting an April low of $45.11, a jump of 38%.

Although the outlook for biotech appears to be sunny, investing in equities comes with risks and implementing an exit strategy is a great way to mitigate these risks. According to the latest data from, an uptrend in the previously mentioned ETFs and stocks would be in trouble at the following price points: PBE at $15.36; IBB at $75.76; AMGN at $58.88. Keep in mind that these price levels change on a daily basis.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos